Scinai Immunotherapeutics Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SCNI Nasdaq 2836 www.scinai.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scinai Immunotherapeutics Ltd.

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Jan 7th, 2026 5:00 am
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Dec 2nd, 2025 6:50 am
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities - Oct 6th, 2025 5:30 am
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Sep 2nd, 2025 5:30 am
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - Jul 29th, 2025 5:15 am
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Jun 26th, 2025 5:30 am
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - Jun 12th, 2025 6:00 am
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Jun 5th, 2025 7:00 am
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - May 30th, 2025 5:00 am
Scinai Announces Annual Financial Results for 2024 - May 7th, 2025 2:01 pm
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases - May 1st, 2025 5:00 am
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions - Mar 27th, 2025 7:25 am
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 - Mar 17th, 2025 5:00 am
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT - Mar 5th, 2025 5:30 am